Status:
COMPLETED
Immunogenicity and Safety of V70P5 Revaccination Subjects
Lead Sponsor:
Novartis Vaccines
Conditions:
Influenza
Eligibility:
All Genders
18-96 years
Phase:
PHASE3
Brief Summary
This study will evaluate the safety and immunogenicity of children previously primed in the V70P5 study when revaccinated with adjuvanted or unadjuvanted seasonal influenza vaccine.
Eligibility Criteria
Inclusion
- Healthy male or female children that have previously participated in the V70P5 study in Finland.
Exclusion
- Any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives.
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
197 Patients enrolled
Trial Details
Trial ID
NCT01210898
Start Date
September 1 2010
End Date
December 1 2011
Last Update
December 1 2016
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tampere Medical School, Vaccine Research Center / Tampere yliopisto rokotetutkimuskeskus
Biokatu 10, Tampere, Finland, FI-33520
2
Helsinki South, Vaccine Research Clinic, Vuorikatu 18, 3 floor
Helsinki, Finland, FI-00100
3
Helsinki East, Vaccine Research Clinic, Itäkeskuksen kauppakeskus/Agenttitalo, Turunlinnantie 8, 4.floor
Helsinki, Finland, FI-00930
4
Järvenpää, Vaccine Research Clinic, Yhteiskouluntie 17
Jarvenpaa, Finland, FI-04400